Axsome Therapeutics (AXSM) PT Raised to $196 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts AXSM Hot Sheet
Price: $140.00 +2.93%
Rating Summary:
27 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Rating Summary:
27 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Join SI Premium – FREE
Morgan Stanley analyst Sean Laaman raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $196.00 (from $194.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Axsome Therapeutics (AXSM) PT Lowered to $250 at Guggenheim
- Tower Semiconductor (TSEM) PT Lowered to $235 at Stifel
- Axsome Therapeutics (AXSM) PT Raised to $249 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
